tetano
Editor, Senior Moderator
J Infect Dis
. 2022 Sep 17;jiac346.
doi: 10.1093/infdis/jiac346. Online ahead of print.
Outcomes of Bebtelovimab Treatment is Comparable to Ritonavir-boosted Nirmatrelvir among High-Risk Patients with Coronavirus Disease-2019 during SARS-CoV-2 BA.2 Omicron Epoch
Raymund R Razonable[SUP] 1 [/SUP], John C O'Horo[SUP] 1 [/SUP], Sara N Hanson[SUP] 2 [/SUP], Richard F Arndt[SUP] 3 [/SUP], Leigh L Speicher[SUP] 4 [/SUP], Teresa A Seville[SUP] 5 [/SUP], Scott T Hall[SUP] 6 [/SUP], Marsha L Pike[SUP] 1 [/SUP], Alexander Heyliger[SUP] 1 [/SUP], Jennifer J Larsen[SUP] 1 [/SUP], Ravindra Ganesh[SUP] 1 [/SUP], Sidna M Tulledge-Scheitel[SUP] 1 [/SUP]
Affiliations
Abstract
The effectiveness of bebtelovimab in real-world settings has not been assessed. In this retrospective cohort study of 3,607 high-risk patients, bebtelovimab was used more commonly than nirmatrelvir-ritonavir for treatment of COVID-19 among older patients, immunosuppressed patients, and those with multiple comorbidities. Despite its use in highly comorbid patients, the rates of progression to severe disease after bebtelovimab (1.4%; 95% confidence interval: 1.2, 1.7) was not significantly different from nirmatrelvir-ritonavir treatment (1.2%; 95% confidence interval: 0.8, 1.5). Our findings support the emergency use authorization of bebtelovimab for treatment of COVID-19 during the Omicron epoch dominated by BA.2 and subvariants.
Keywords: SARS-CoV-2; bebtelovimab; covid-19; hospitalization; monoclonal antibodies; nirmatrelvir; paxlovid; ritonavir.
. 2022 Sep 17;jiac346.
doi: 10.1093/infdis/jiac346. Online ahead of print.
Outcomes of Bebtelovimab Treatment is Comparable to Ritonavir-boosted Nirmatrelvir among High-Risk Patients with Coronavirus Disease-2019 during SARS-CoV-2 BA.2 Omicron Epoch
Raymund R Razonable[SUP] 1 [/SUP], John C O'Horo[SUP] 1 [/SUP], Sara N Hanson[SUP] 2 [/SUP], Richard F Arndt[SUP] 3 [/SUP], Leigh L Speicher[SUP] 4 [/SUP], Teresa A Seville[SUP] 5 [/SUP], Scott T Hall[SUP] 6 [/SUP], Marsha L Pike[SUP] 1 [/SUP], Alexander Heyliger[SUP] 1 [/SUP], Jennifer J Larsen[SUP] 1 [/SUP], Ravindra Ganesh[SUP] 1 [/SUP], Sidna M Tulledge-Scheitel[SUP] 1 [/SUP]
Affiliations
- PMID: 36124696
- DOI: 10.1093/infdis/jiac346
Abstract
The effectiveness of bebtelovimab in real-world settings has not been assessed. In this retrospective cohort study of 3,607 high-risk patients, bebtelovimab was used more commonly than nirmatrelvir-ritonavir for treatment of COVID-19 among older patients, immunosuppressed patients, and those with multiple comorbidities. Despite its use in highly comorbid patients, the rates of progression to severe disease after bebtelovimab (1.4%; 95% confidence interval: 1.2, 1.7) was not significantly different from nirmatrelvir-ritonavir treatment (1.2%; 95% confidence interval: 0.8, 1.5). Our findings support the emergency use authorization of bebtelovimab for treatment of COVID-19 during the Omicron epoch dominated by BA.2 and subvariants.
Keywords: SARS-CoV-2; bebtelovimab; covid-19; hospitalization; monoclonal antibodies; nirmatrelvir; paxlovid; ritonavir.